[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Forte Biosciences (FBRX) ripped higher on Monday after the Dutch immunology giant, Argenx (ARGX), announced a definitive agreement to acquire it for $2.2 billion. The all-cash transaction is expected to close in the third quarter of 2026 and values FBRX shares at $77 each, representing a huge 40% upside on their previous close.

Following today’s gains, Forte Biosciences stock is trading at more than 3.5x its price at the start of this year. 

Fundamentals

See More
  • Market Capitalization, $K 55,605,472
  • Shares Outstanding, K 62,561
  • Annual Sales, $ 4,248 M
  • Annual Income, $ 1,292 M
  • EBIT $ 1,602 M
  • EBITDA $ 1,630 M
  • 60-Month Beta 0.45
  • Price/Sales 13.52
  • Price/Cash Flow 43.04
  • Price/Book 6.82

Options Overview Details

View History
  • Implied Volatility 38.24% (+0.08%)
  • Historical Volatility 42.73%
  • IV Percentile 66%
  • IV Rank 59.68%
  • IV High 46.46% on 10/28/25
  • IV Low 26.07% on 08/06/25
  • Expected Move (DTE 23) 19.64 (2.25%)
  • Put/Call Vol Ratio 5.10
  • Today's Volume 177
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 5,706
  • Open Int (30-Day) 5,355
  • Expected Range 852.60 to 891.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $7.27
  • Number of Estimates 8
  • High Estimate $8.75
  • Low Estimate $6.39
  • Prior Year $5.18
  • Growth Rate Est. (year over year) +40.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
843.59 +3.40%
on 07/17/26
953.58 -8.53%
on 07/02/26
-14.95 (-1.69%)
since 06/26/26
3-Month
754.84 +15.55%
on 04/29/26
953.58 -8.53%
on 07/02/26
+97.20 (+12.54%)
since 04/28/26
52-Week
590.78 +47.64%
on 07/29/25
953.58 -8.53%
on 07/02/26
+277.04 (+46.55%)
since 07/28/25

Most Recent Stories

More News
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Forte Biosciences ...

FBRX : 76.65 (+0.20%)
ARGX : 872.23 (-1.87%)
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Forte Biosciences stock soars on a $2.2 billion takeover proposal from Argenx. But is there any further upside left in FBRX shares? Let’s find out!

FBRX : 76.65 (+0.20%)
ARGX : 872.23 (-1.87%)
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth ...

FBRX : 76.65 (+0.20%)
ARGX : 872.23 (-1.87%)
Argenx's Autoimmune Expansion Beyond Myasthenia Gravis Enters Its Proving Window

Barchart Research What to Expect from ARGX Earnings ARGX Generated July 22, 2026 Current Price $851.72 EPS Estimate $$6.13 Consensus Rating Strong Buy Average Move 5.01% Argenx's Autoimmune Expansion Beyond...

ARGX : 872.23 (-1.87%)
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability...

ARGX : 872.23 (-1.87%)
The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...

CGEM : 17.47 (+0.23%)
IDXX : 569.54 (+2.40%)
IPA : 2.07 (+7.25%)
ARGX : 872.23 (-1.87%)
XNCR : 19.97 (+0.55%)
HYFT : 1.3600 (-5.56%)
2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

NVO : 50.96 (+2.60%)
IBB : 190.52 (+1.16%)
ARGX : 872.23 (-1.87%)
PFE : 25.25 (+2.35%)
XBI : 149.78 (-0.54%)
argenex Q1 Earnings Call Highlights

argenx (NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across multiple late-stage pipeline programs, while newly appointed CEO Karen...

ARGX : 872.23 (-1.87%)
Argenx Reports Tomorrow With Analysts Apparently Forgetting What Biotech Valuations Mean

Barchart Research What to Expect from ARGX Earnings ARGX Generated May 6, 2026 Current Price $807.55 EPS Estimate $$5.16 Consensus Rating Strong Buy Average Move 4.81% Argenx Reports Tomorrow With Analysts...

ARGX : 872.23 (-1.87%)
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

TORONTO , Nov. 5, 2025 /CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

ARGX : 872.23 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

3rd Resistance Point 914.12
2nd Resistance Point 904.85
1st Resistance Point 888.54
Last Price 872.23
1st Support Level 862.96
2nd Support Level 853.69
3rd Support Level 837.38

See More

52-Week High 953.58
Last Price 872.23
Fibonacci 61.8% 814.99
Fibonacci 50% 772.18
Fibonacci 38.2% 729.37
52-Week Low 590.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.